Pursuant to Regulation 30 and Schedule III (A) (7) of the Listing and Disclosure Requirements Regulations, 2015, GlaxoSmithKline Pharmaceutical has informed that Pradeep V. Bhide (Din: 03304262) has voluntarily relinquished his position as Board member with effect from closing hours of 7th January 2025. He has confirmed that there are no other material reasons other than provided in the resignation letter. Further Pradeep V. Bhide is on the Board of the company and is a committee member of the Audit & Risk Management Committee. The company has enclosed a copy of the resignation letter along with detailed reasons for resignation as submitted by Pradeep V. Bhide to the Board of the Company. The Company places on record its appreciation for the guidance and support provided by Pradeep V. Bhide during his long tenure.
The above information is a part of company’s filings submitted to BSE.
